Visual prognosis in retinoblastoma patients with multimodality treatments: Visual Prognosis in Retinoblastoma Patients
Issued Date
2024-12-11
Resource Type
eISSN
29502535
Scopus ID
2-s2.0-85216984715
Journal Title
AJO International
Volume
1
Issue
4
Rights Holder(s)
SCOPUS
Bibliographic Citation
AJO International Vol.1 No.4 (2024)
Suggested Citation
Chokchaitanasin R., Asawaworarit N., Dieosuthichat W., Hongeng S., Pakakasama S., Anurathapan U., Songdej D., Pongphitcha P., Aroonroch R., Kaewkhaw R., Chanthanaphak E., Rojanaporn D. Visual prognosis in retinoblastoma patients with multimodality treatments: Visual Prognosis in Retinoblastoma Patients. AJO International Vol.1 No.4 (2024). doi:10.1016/j.ajoint.2024.100051 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/104265
Title
Visual prognosis in retinoblastoma patients with multimodality treatments: Visual Prognosis in Retinoblastoma Patients
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: This study evaluates factors associated with globe preservation and long-term visual outcomes according to clinical characteristics and treatment modalities in intraocular retinoblastoma patients. Design: A retrospective review of medical records enrolled intraocular retinoblastoma patients between January 1, 2007, and June 30, 2020. Methods: • Setting: Single-centered. • Patient or study population: Intraocular retinoblastoma patients treated at Ramathibodi Hospital, Bangkok, Thailand. • Main outcome measure: A statistically significant factor associated with visual prognosis corresponds to baseline characteristics, staging, anatomical involvement, and multimodal treatments. Results: 86 patients (124 eyes) were included. Median age of disease bilaterality onset was significantly younger than unilaterality. Three-quarters of patients were in advanced stages (groups D or E in either ICRB or IIRC and up to cT2a from AJCC). Globe salvage rate was 54.0 % (67 eyes). ICRB Groups D-E, IIRC Groups D-E, and AJCC cT2a and more advanced stages are the globe removal-associated independent risk factors (adjusted odds ratio [AOR] [95 % CI] = 7.40 [1.36, 40.09], 8.33 [1.55, 44.73], 14.73 [1.55, 139.79], respectively). Compared to other classification, IIRC provided the highest statistical correlation from univariate analysis. IIRC Groups A-C is a good visual acuity-associated independent risk factor (AOR [95 % CI] = 4.64 [1.05, 20.43] and P = 0.042). Macular involvement is a worse visual acuity-associated independent risk factor (AOR [95 % CI] = 0.14 [0.02, 0.82] and P = 0.03). Systemic chemotherapy (86.29 %) is the mainstay treatment in our study and is the only good visual outcome-associated treatment. Subgroup analysis of all eyes receiving systemic chemotherapy reveals statistically significant preventive factors for globe removal for tumor staging with ICRB and IIRC groups A-C and AJCC stages cT1a–cT1b (odds ratio [95 % CI] = 15.75 [4.38, 56.65], 15.67 [4.34, 56.53], 9.97 [2.75, 36.18], respectively; P=<0.001) and prevents the worse visual outcome in these stages, (odds ratios [95 % CI] = 4.57 [1.28, 16.27], 6.61 [1.74, 25.11], and 7.50 [1.86, 30.16], respectively; P =< 0.05). Conclusions: All recent advanced clinical stagings are globe removal outcome-associated independent risk factors. IIRC staging is the best visual results predictor. IIRC Groups A-C were associated with a good visual outcome. Macular involvement tumors are strongly associated with poor visual outcome, despite successful globe preservation from multimodality treatment. Systemic chemotherapy remains a crucial globe-saving treatment and prevents worse vision–especially in ICRB and IIRC Groups A-C and AJCC stage cT1a-cT1b.